Renaissance Technologies
LYEL icon

Renaissance Technologies’s Lyell Immunopharma LYEL Stock Holding History

Renaissance Technologies’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.34M Buy
116,411
+76,921
+195% +$1.8M ﹤0.01% 1818
2025
Q4 		$1.22M Sell
39,490
-24,500
-38% -$548K ﹤0.01% 2174
2025
Q3 		$1.04M Sell
63,990
-3,200
-5% -$36.5K ﹤0.01% 2461
2025
Q2 		$594K Sell
67,190
-21,235
-24% -$194K ﹤0.01% 2753
2025
Q1 		$951K Buy
88,425
+7,818
+10% +$95.8K ﹤0.01% 2457
2024
Q4 		$1.03M Buy
80,607
+70,737
+717% +$1.4M ﹤0.01% 2482
2024
Q3 		$272K Buy
9,870
+2,255
+30% +$66.3K ﹤0.01% 3010
2024
Q2 		$221K Sell
7,615
-13,560
-64% -$646K ﹤0.01% 3011
2024
Q1 		$944K Buy
21,175
+17,550
+484% +$751K ﹤0.01% 2523
2023
Q4 		$141K Buy
+3,625
New +$131K ﹤0.01% 3226
2022
Q4 		– Sell
-2,035
Closed -$298K – 4280
2022
Q3 		$298K Sell
2,035
-475
-19% -$64.3K ﹤0.01% 3216
2022
Q2 		$327K Sell
2,510
-165
-6% -$16.9K ﹤0.01% 3404
2022
Q1 		$270K Buy
+2,675
New +$324K ﹤0.01% 3515

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies's LYEL Position: Q1 2026 in Review

Renaissance Technologies increased its Lyell Immunopharma (LYEL) stake by 195% in Q1 2026, buying an estimated $1.8M and bringing the position to 116,411 shares worth $2.34M. The position accounts for ﹤0.01% of the portfolio, ranked #1818.

Renaissance Technologies first reported a position in LYEL in Q1 2022 and has held it in 13 quarters since. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • Renaissance Technologies held 116,411 shares of Lyell Immunopharma worth $2.34M as of Q1 2026.
  • Renaissance Technologies bought 76,921 Lyell Immunopharma shares in Q1 2026, an estimated $1.8M.
  • Lyell Immunopharma made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #1818 holding.
  • Renaissance Technologies first reported a position in Lyell Immunopharma in Q1 2022 and has held it in 13 quarters since.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.